Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -1K | 0 | 0 | 0 | 0 |
| Operating Income | -22M | -65M | -16K | -28K | -27K |
| EBITDA | -22M | -28M | -15K | -27K | -26K |
| Net Income | -50M | -63M | -16K | -27K | -26K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.916
+5.90% today
1Y Change
-26.00%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rein Therapeutics Inc. (RNTX) is a Healthcare stock with a market cap of $30.00M and listed on NASDAQ. The stock last traded around $0.92 and down 26.0% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +44.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +44.2%, free cash flow +13.1% with operating margin 0.0% and ROIC -120.3%. Stock Foundry combines RNTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RNTX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RNTX Max Drawdown
-48.43%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RNTX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$26.2K
+4.3% YoY
Free Cash Flow
-$23.9M
+3.8% YoY
Revenue Growth
+0.0%
EPS Growth
+44.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -1K | 0 | 0 | 0 | 0 |
| Operating Income | -22M | -65M | -16K | -28K | -27K |
| EBITDA | -22M | -28M | -15K | -27K | -26K |
| Net Income | -50M | -63M | -16K | -27K | -26K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3M | 13M | 17M | 5M | 4M |
| Total Assets | 24M | 69M | 106M | 22M | 48M |
| Total Liabilities | 7M | 15M | 99M | 3M | 5M |
| Shareholder Equity | 17M | 54M | 7M | 19M | 44M |
| Total Debt | 0 | 0 | 48K | 33K | 162K |
| Net Debt | -3M | -13M | -17M | -5M | -3M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
24M
+4.5% YoY
Capital Expenditures
157K
Free Cash Flow
24M
+3.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-281.0%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.